Ocuphire Pharma Analyst Ratings
Buy Rating Affirmed: Ocuphire Pharma's APX3330 Shows Promise for Diabetic Retinopathy and Pipeline Progress
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)
Ocuphire Pharma Analyst Ratings
Ocuphire Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)
Buy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatment
Buy Rating Affirmed for Ocuphire Pharma on Promising Clinical Advancements and Strategic Partnerships
HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
Ocuphire Pharma Analyst Ratings
Promising Developments and FDA Approval Boost Ocuphire Pharma's Prospects: An Analysis of Buy Rating Factors
Promising FDA Feedback and Potential Market Opportunities Drive Buy Rating for Ocuphire Pharma
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Ocuphire Pharma (OCUP)
Buy Rating for Ocuphire Pharma: FDA Approval of Ryzumvi and Anticipated Developments Boost Stock's Value
Ocuphire Pharma Analyst Ratings
Ocuphire Pharma (OCUP) Receives a Rating Update From a Top Analyst
HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
Ocuphire Pharma (OCUP) Gets a Buy From JonesTrading
JonesTrading Reaffirms Their Buy Rating on Ocuphire Pharma (OCUP)
H.C. Wainwright Remains a Buy on Ocuphire Pharma (OCUP)